ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Services

IHH Healthcare Bhd.

Company Background

IHH Healthcare runs 37 private hospitals in 10 countries, including China and India. Its facilities have a total of more than 6,000 beds.

Headquartered in Malaysia, the company also sees Singapore and Turkey as its home markets. Its hospitals in these three countries attract affluent patients from across Southeast Asia and the Middle East. The group's Mount Elizabeth and Gleneagles hospitals in Singapore are considered particularly prestigious, thanks to their state-of-the-art medical equipment.

IHH is 44% owned by Khazanah Nasional, an investment arm of the Malaysian government. Khazanah in 2010 defeated a rival bid from India's Fortis Healthcare to take control of Parkway Holdings, a then-listed Singaporean company, which owned hospitals in Malaysia and Singapore. Today, Parkway is a wholly owned IHH subsidiary.

IHH is listed in both Malaysia and Singapore. The group is led by CEO Tan See Leng, who is also a doctor. Tan joined Parkway in 2004 and held various high-ranking positions before the company slid under IHH's umbrella.

Globally, IHH is the second-largest health care operator by market capitalization. Japanese trading house Mitsui & Co. is a major shareholder.

Business Summary

IHH Healthcare Bhd. is an investment holding company, which engages in the provision of healthcare services. It operates through the following segments: Parkway Pantai, PPL Others, CEEMENA, and Others. The Parkway Pantai segment comprises the Parkway Pantai and PLife REIT. The PPL Others segment includes Pantai's hospital in Brunei, and corporate office as well as other investment holding entities within Parkway Pantai. The CEEMENA segment refers to Central and Eastern Europe, Middle East, and North Africa. The company was founded on May 21, 2010 and is headquartered in Kuala Lumpur, Malaysia.

Financial Highlights

Dec 2018 MYRUSD
Gross Profit2,902.27M719.20M
Operating income1,240.72M307.46M
Income before tax739.05M183.14M
Net income541.84M134.27M
Diluted EPS0.060.01
Dividends Per Share0.030.00
Total Assets45,114.51M10,917.00M
Total liabilities18,765.36M4,540.92M
Total equity21,994.00M5,322.20M
Operating cash flow1,562.71M387.25M
Currency in MYRCurrency in USD

Historical Data

 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 7,344.01M 8,455.46M 10,021.88M 11,142.63M 11,520.93M
Gross Profit 2,020.36M 2,327.18M 2,657.91M 2,620.19M 2,902.27M
Operating income 1,074.16M 1,210.55M 1,227.74M 1,068.88M 1,240.72M
Income before tax 1,211.32M 1,203.25M 860.94M 1,162.33M 739.05M
Net income 754.29M 933.90M 612.35M 931.31M 541.84M
EBITDA 1,682.34M 1,900.05M 2,026.87M 2,046.96M 2,162.14M
Diluted EPS 0.09 0.11 0.07 0.11 0.06
Dividends Per Share 0.03 0.03 0.03 0.03 0.03
Total Assets 28,680.13M 35,517.48M 37,200.39M 38,925.48M 45,114.51M
Total liabilities 7,366.73M 11,280.78M 13,307.23M 15,183.41M 18,765.36M
Total equity 19,451.74M 22,155.73M 21,985.74M 21,890.16M 21,994.00M
Operating cash flow 1,557.92M 1,863.97M 1,730.45M 2,006.03M 1,562.71M
 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 2,244.48M 2,162.70M 2,419.15M 2,591.60M 2,854.98M
Gross Profit 617.46M 595.23M 641.58M 609.41M 719.20M
Operating income 328.28M 309.63M 296.36M 248.60M 307.46M
Income before tax 370.20M 307.76M 207.82M 270.34M 183.14M
Net income 230.52M 238.86M 147.81M 216.60M 134.27M
EBITDA 514.16M 485.98M 489.26M 476.09M 535.79M
Diluted EPS 0.02 0.02 0.01 0.02 0.01
Dividends Per Share 0.00 0.00 0.00 0.00 0.00
Total Assets 8,202.52M 8,272.38M 8,292.55M 9,618.35M 10,917.00M
Total liabilities 2,106.88M 2,627.40M 2,966.39M 3,751.77M 4,540.92M
Total equity 5,563.20M 5,160.29M 4,900.96M 5,408.98M 5,322.20M
Operating cash flow 476.13M 476.75M 417.70M 466.57M 387.25M

Valuation Measures

Dec 2018
Operating margin10.76%
Profit margin4.70%

Key executives

  • Chief Executive Officer & Executive Director: Chi-Keon Loh
  • Group Chief Operating Officer: Suet Wun Lim
  • Group Chief Financial Officer: Soon Teck Low
  • Head-Strategic Planning & Business Development: Boon Kheng Chan
  • Group Head-Internal Audit: Audrey Huang


  • Mitsui & Co., Ltd. (32.9%)
  • Khazanah Nasional Bhd. (Investment Company) (26.0%)
  • Employees Provident Fund (7.3%)
  • Permodalan Nasional Bhd. (4.8%)
  • Public Mutual Bhd. (2.1%)
  • Kuwait Investment Authority (Investment Management) (1.6%)
  • Kumpulan Wang Persaraan (1.5%)
  • The Vanguard Group, Inc. (1.1%)
  • GIC Pte Ltd. (Investment Management) (1.0%)

Contact Details

  • Website:
  • Address: Level 11 Block A, Pantai Hospital, Kuala Lumpur, 8 Jalan Bukit Pantai, Kuala Lumpur, 59100, Malaysia
  • Phone: +60.3.2298.9898

Related Companies

  • Northern TK Venture Pte Ltd.
  • IHH Healthcare Bhd. (Singapore)
  • Centre For Digestive & Kidney Diseases India Pvt Ltd.
  • Acibadem Saglik Yatirimlari Holding AS
  • Indah Capital Ltd.
  • Shanghai Mai Kang Hospital Investment Management Co. Ltd.
  • Bodrum Tedavi Hizmetleri A.S
  • Integrated Healthcare Turkey Yatirimlari Ltd.
  • Gleneagles Development Pte Ltd.
  • Integrated Healthcare Holdings Ltd.
  • Acibadem Saglik Hizmetleri ve Ticaret AS
  • Pantai Holdings Sdn. Bhd.
  • Parkway Holdings Ltd.


    Last Updated on 22 Jan, 2020

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Get Unlimited access

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends January 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media